Use of levocetirizine and montelukast in the treatment of autoimmune disorders
The embodiments described herein include methods and formulations for treating autoimmune disorders. The methods and formulations include, but are not limited to, methods and formulations for delivering effective concentrations of levocetirizine and montelukast to a patient in need. The methods and formulations can comprise conventional and/or modified-release elements, providing for drug delivery to the patient.
1. A method of treating an autoimmune disorder or a symptom of an autoimmune disorder in a patient in need thereof comprising administering to the patient an effective amount of a combination of levocetirizine and montelukast, wherein the autoimmune disorder is idiopathic thrombocytopenia purpura.
2. The method of claim 1 , wherein the combination is administered at the onset of symptoms.
3. The method of claim 1 , wherein the combination is administered in a sequential manner.
4. The method of claim 1 , wherein the combination is administered in a substantially simultaneous manner.
5. The method of claim 1 , wherein the combination is administered to the patient by one or more of the routes consisting of enteral, intravenous, intraperitoneal, inhalation, intramuscular, subcutaneous and oral.
6. The method of claim 1 , wherein the levocetirizine and montelukast are administered by the same route.
7. The method of claim 1 , further comprising the administration of an additional active agent.
8. The method of claim 7 , wherein the additional active agent is a steroid.
9. The method of claim 7 , wherein the additional active agent is a glucocorticoid.
10. The method of claim 8 , wherein the glucocorticoid is prednisone.
11. The method of claim 8 , wherein the glucocorticoid is methyl-prednisolone.
12. The method of claim 7 , wherein the additional active agent is an immunosuppressant.
13. The method of claim 12 , wherein the immunosuppressant is methotrexate.
14. The method of claim 7 , wherein the additional active agent is a supplement.
15. The method of claim 14 , wherein the supplement is ferrous gluconate.
16. The method of claim 14 , wherein the supplement is vitamin C.
17. The method of claim 7 , wherein the additional active agent is an antibacterial.
18. The method of claim 17 , wherein the additional active agent is dapsone.
19. The method of claim 7 , wherein the additional active agent is a protein.
20. The method of claim 19 , wherein the protein is filgrastim.
21. The method of claim 7 , wherein the additional active agent is an immunomodulator.
22. The method of claim 21 , wherein the immunomodulator is lenalidomide.